Chapter 1

Where the story stands

Vital Farms sells pasture-raised eggs at a premium to conventional eggs. Between fiscal 2021 and 2025 revenue nearly tripled to $759 million and the business swung from break-even to $66 million of net income. Then the share price fell roughly 75% from its August 2025 high to about $13. This chapter orients a reader new to the name and fixes the question the rest of the report works through: how much of that growth was the brand, and how much was the price of ordinary eggs.

What the company sells

Vital Farms was founded in 2007 on a 27-acre plot in Austin, Texas, and is today a Delaware public benefit corporation and Certified B Corporation that sources eggs and butter through a distributed supply chain of small farms [1]. Rather than own large flocks, it contracts a network of more than 600 small family farms that meet its pasture-raised animal-welfare standard, then washes, grades and packs the eggs itself [2]. Shell eggs are the business: they were about 93% of net revenue in fiscal 2025, with butter and other products making up the rest [3].

The product reaches consumers through mainstream and natural grocers — Kroger, Publix, Target, Walmart, Sprouts and Whole Foods among them. As of December 2025 Vital Farms was the number one or two branded egg by retail dollar sales at nine of its ten largest customers [4]. Processing runs through Egg Central Station in Springfield, Missouri — capable of packing more than 7.5 million eggs a day — and the company is building a second automated facility, Vital Crossroads, in Seymour, Indiana [5].

Source: FY2025 Annual Report (Form 10-K) and reported market data; price and shares as of July 24, 2026 [6].

Five years of compounding

The financial record is unusual for a fresh-food company. Net revenue rose from $471.9 million in fiscal 2023 to $606.3 million in 2024 to $759.4 million in 2025 — the tail end of a run that lifted revenue from $261 million in 2021, a compound rate above 30% a year [7]. Profitability arrived with scale: operating income went from essentially zero in 2021 and 2022 to $88 million in 2025, as gross margin widened from about 30% to the high-30s.

Source: FY2021–FY2025 Annual Reports (Form 10-K), Consolidated Statements of Operations, as reported [8].

The balance sheet keeps pace with the income statement. At the end of fiscal 2025 Vital Farms held $48.8 million of cash against $351 million of equity and no funded debt; the drop in cash from $151 million a year earlier reflects spending on the Indiana facility, not losses. For an investor who wants the chance of bankruptcy near zero, that is the first thing worth knowing: the company does not owe anyone money, and it earns its way. A full financial history — three years back and consensus estimates forward — is left to its own chapter rather than compressed here.

The re-rating

The stock tells a different story than the income statement. Vital Farms came public in 2020, drifted for three years, then ran from roughly $12 in early 2023 to an all-time high of $52.47 in August 2025 as the growth and margin numbers above landed. From that peak it has fallen about 75%, with most of the decline concentrated between the February 2026 full-year report and the spring, and it now trades near $13 — close to its 52-week low.

Source: company share price history, as reported.

What broke

The premium Vital Farms charges is priced against conventional eggs, and for two years that reference point moved in its favor. Recurring outbreaks of highly pathogenic avian influenza thinned the supply of conventional eggs; in fiscal 2024 and 2025 those disruptions "resulted at times in increased demand for premium egg products such as ours," at points emptying competitors' shelves [9]. When ordinary eggs are scarce and expensive, the extra dollars for pasture-raised look smaller, and new shoppers try the brand.

In early 2026 that reversed. Conventional egg prices fell faster than underlying costs, and the gap between Vital Farms and the shelf around it widened to levels management said it had not seen before. Existing buyers stayed loyal, but first-time trial dropped — households new to the brand fell from more than 55% of buyers in 2024 and 2025 to about 50% in the first quarter of 2026 — and velocity slowed enough that the company cut its full-year guidance [10]. Management's own evidence frames both the problem and its fix: in markets where the price gap widened most, volume growth turned negative, and at one top-10 customer, narrowing the gap from about 35% to 25% above competing premium eggs lifted volumes 18% in two weeks [11]. Closing that gap means giving back price and margin in a year the company is also funding a new plant — which is why consensus now expects roughly flat revenue and a small loss in fiscal 2026 before a return to growth in 2027.

Source: FY2024–FY2025 Annual Reports (Form 10-K), as reported, and consensus analyst estimates for FY2026–FY2027 [12].

Consensus carries a fiscal-2026 loss of about $0.42 a share against $1.44 earned in 2025, recovering to roughly $0.44 in 2027 — a reset year, on the current read, rather than a broken business.

The question this report answers

The central question is whether Vital Farms is a durable, category-leading brand whose collapsed price reflects a temporary, largely self-fixable widening of its premium to conventional eggs — or whether much of the 2023–2025 surge was a cyclical windfall from avian-flu-inflated egg prices that is now unwinding, leaving a slower, thinner-margin business than the peak implied. The evidence for the first read is real trial and shelf leadership built over years and a debt-free balance sheet that makes the reset survivable; the strongest fact against it is that the same price gap the company now blames for stalling growth is the one that flattered it on the way up. What would settle it is whether narrowing the gap restores new-household trial without permanently resetting margins lower — the thread the chapters that follow pick up.